PROS1 and B cell deficiency: A prior clinical study of patients with B cell deficiencies receiving bamlanivimab therapy observed mutations arising in the SARS-CoV-2 spike protein in two subjects, however, spike mutations were not detected until days 28 and 51 post first positive test [111].